Intravital FLIM-FRET imaging reveals dasatinib-induced spatial control of Src in pancreatic cancer

Cancer Research

Volumn 73, Issue 15, 2013, Pages 4674-4686

  Nobis, Max ^a   McGhee, Ewan J ^a   Morton, Jennifer P ^a   Schwarz, Juliane P ^a   Karim, Saadia A ^a   Quinn, Jean ^b   Edward, Mike ^b   Campbell, Andrew D ^a   McGarry, Lynn C ^a   Evans, T R Jeffry ^a   Brunton, Valerie G ^c   Frame, Margaret C ^c   Carragher, Neil O ^c   Wang, Yingxiao ^d   Sansom, Owen J ^a   Timpson, Paul ^a,e   Anderson, Kurt I ^a  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d University of Illinois at Urbana Champaign   (United States)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPAMINE; DASATINIB; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOSENSOR; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFICACY; DRUG PENETRATION; DRUG RESPONSE; DRUG TARGETING; FLUORESCENCE LIFETIME IMAGING MICROSCOPY; FLUORESCENCE MICROSCOPY; FLUORESCENCE RESONANCE ENERGY TRANSFER; METASTASIS INHIBITION; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOSENSING TECHNIQUES; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FLUORESCENCE RESONANCE ENERGY TRANSFER; IMAGING, THREE-DIMENSIONAL; MICE; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; PANCREATIC NEOPLASMS; PYRIMIDINES; SRC-FAMILY KINASES; THIAZOLES;

EID: 84881455207     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-4545     Document Type: Article

References (55)

1. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature 2008;452:580-9.
2. Timpson P, McGhee EJ, Anderson KI. Imaging molecular dynamics in vivo-from cell biology to animal models. J Cell Sci 2011;124:2877-90.
3. Giepmans BN, Adams SR, Ellisman MH, Tsien RY. The fluorescent toolbox for assessing protein location and function. Science 2006;312: 217-24.
4. Beerling E, Ritsma L, Vrisekoop N, Derksen PW, van Rheenen J. Intravital microscopy: new insights into metastasis of tumors. J Cell Sci 2011;124:299-310.
5. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004; 363:1049-57.
6. Jensen OM, Esteve J, Moller H, Renard H. Cancer in the European Community and its member states. Eur J Cancer 1990;26:1167-256.
7. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992;326:455-65.
8. Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 2013;62:112-20.
9. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012; 21:418-29.
10. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457-61.
11. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005;7:469-83.
12. Olive KP, Tuveson DA. The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin Cancer Res 2006; 12:5277-87.
13. Hruban RH, Adsay NV, Albores-Saavedra J, Anver MR, Biankin AV, Boivin GP, et al. Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res 2006;66:95-106.
14. Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, Doyle B, et al. Mutant p53 drives metastasis and overcomes growth arrest/ senescence in pancreatic cancer. Proc Natl Acad Sci U S A 2010;107: 246-51.
15. Muller PA, Vousden KH, Norman JC. p53 and its mutants in tumor cell migration and invasion. J Cell Biol 2011;192:209-18.
16. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, et al. A mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009;137:87-98.
17. Girardini JE, Napoli M, Piazza S, Rustighi A, Marotta C, Radaelli E, et al. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell 2011;20:79-91.
18. Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S, et al. Mutant p53 drives invasion by promoting integrin recycling. Cell 2009;139:1327-41.
19. Timpson P, McGhee EJ, Morton JP, von Kriegsheim A, Schwarz JP, Karim SA, et al. Spatial regulation of RhoA activity during pancreatic cancer cell invasion driven by mutant p53. Cancer Res 2011;71: 747-57.
20. Muller PA, Trinidad AG, Timpson P, Morton JP, Zanivan S, van den Berghe PV, et al. Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene 2013;32:1252-65.
21. Brunton VG, Frame MC. Src and focal adhesion kinase as therapeutic targets in cancer. Curr Opin Pharmacol 2008;8:427-32.
22. Frame MC. Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta 2002;1602:114-30.
23. Lutz MP, Esser IB, Flossmann-Kast BB, Vogelmann R, Luhrs H, Friess H, et al. Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun 1998; 243:503-8.
24. Hakam A, Fang Q, Karl R, Coppola D. Coexpression of IGF-1R and c- Src proteins in human pancreatic ductal adenocarcinoma. Dig Dis Sci 2003;48:1972-8.
25. Morton JP, KarimSA, Graham K, Timpson P, Jamieson N, Athineos D, et al. Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 2010; 139:292-303.
26. Evans TRJ, Van Cutsem E,Moore MJ, Purvis JD, Strauss LC, Rock EP, et al. Dasatinib combined with gemcitabine (Gem) in patients (pts) with locally advanced pancreatic adenocarcinoma (PaCa): design of CA180-375, a placebo-controlled, randomized, double-blind phase II trial. J Clin Oncol 30, 2012 (suppl; abstr TPS4134).
27. Yu M, Tannock IF. Targeting tumor architecture to favor drug penetration: a new weapon to combat chemoresistance in pancreatic cancer? Cancer Cell 2012;21:327-9.
28. Wang Y, Botvinick EL, Zhao Y, Berns MW, Usami S, Tsien RY, et al. Visualizing the mechanical activation of Src. Nature 2005;434:1040-5.
29. Dawson JC, Timpson P, Kalna G, Machesky LM. Mtss1 regulates epidermal growth factor signaling in head and neck squamous carcinoma cells. Oncogene 2012;31:1781-93.
30. Timpson P, McGhee EJ, Erami Z, Nobis M, Quinn JA, Edward M, et al. Organotypic collagen I assay: a malleable platform to assess cell behaviour in a 3-dimensional context. J Visual Exp 2011:13:e3089.
31. Edward M, Gillan C, Micha D, Tammi RH. Tumour regulation of fibroblast hyaluronan expression: a mechanism to facilitate tumour growth and invasion. Carcinogenesis 2005;26:1215-23.
32. Serrels A, Timpson P, Canel M, Schwarz JP, Carragher NO, FrameMC, et al. Real-time study of E-cadherin and membrane dynamics in living animals: implications for disease modeling and drug development. Cancer Res 2009;69:2714-9.
33. Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, et al. Hedgehog is an early and latemediator of pancreatic cancer tumorigenesis. Nature 2003;425:851-6.
34. Cicchi R, Kapsokalyvas D, De Giorgi V, Maio V, Van Wiechen A, Massi D, et al. Scoring of collagen organization in healthy and diseased human dermis by multiphoton microscopy. J Biophotonics 2010;3: 34-43.
35. Canel M, Serrels A, Miller D, Timpson P, Serrels B, Frame MC, et al. Quantitative in vivo imaging of the effects of inhibiting integrin signaling via Src and FAK on cancer cell movement: effects on E-cadherin dynamics. Cancer Res 2010;70:9413-22.
36. Cukierman E, Pankov R, Stevens DR, Yamada KM. Taking cell-matrix adhesions to the third dimension. Science 2001;294:1708-12.
37. Yamada KM, Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell 2007;130:601-10.
38. Dozynkiewicz MA, Jamieson NB, Macpherson I, Grindlay J, van den Berghe PV, von Thun A, et al. Rab25 and CLIC3 collaborate to promote integrin recycling from late endosomes/lysosomes and drive cancer progression. Dev Cell 2012;22:131-45.
39. Lindsay CR, Lawn S, Campbell AD, Faller WJ, Rambow F, Mort RL, et al. P-Rex1 is required for efficient melanoblast migration and melanoma metastasis. Nat Commun 2011;2:555.
40. Olson P, Chu GC, Perry SR, Nolan-Stevaux O, Hanahan D. Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma. Proc Natl Acad Sci U S A 2011;108:E1275-84.
41. Komar G, Kauhanen S, Liukko K, Seppanen M, Kajander S, Ovaska J, et al. Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness. Clin Cancer Res 2009;15: 5511-7.
42. Brekken C, de Lange Davies C. Hyaluronidase reduces the interstitial fluid pressure in solid tumours in a non-linear concentration-dependent manner. Cancer Lett 1998;131:65-70.
43. Samuel MS, Lopez JI, McGhee EJ, Croft DR, Strachan D, Timpson P, et al. Actomyosin-mediated cellular tension drives increased tissue stiffness and beta-catenin activation to induce epidermal hyperplasia and tumor growth. Cancer Cell 2011;19:776-91.
44. Isherwood B, Timpson P, Mcghee EJ, Anderson KI, Canel M, Serrels A, et al. Live cell in vitro and in vivo imaging applications: accelerating drug discovery. Pharmaceutics 2011;3:141-70.
45. Kamb A. What's wrong with our cancer models? Nat Rev Drug Discov 2005;4:161-5.
46. Festy F, Ameer-Beg SM, Ng T, Suhling K. Imaging proteins in vivo using fluorescence lifetime microscopy. Mol Biosyst 2007;3:381-91.
47. Wouters FS, Verveer PJ, Bastiaens PI. Imaging biochemistry inside cells. Trends Cell Biol 2001;11:203-11.
48. Dehmelt L, Bastiaens PI. Spatial organization of intracellular communication: insights from imaging. Nat Rev Mol Cell Biol 2010;11:440-52.
49. Seong J, Ouyang M, Kim T, Sun J, Wen PC, Lu S, et al. Detection of focal adhesion kinase activation at membrane microdomains by fluorescence resonance energy transfer. Nat Commun 2011;2:406.
50. Talbot CB, McGinty J, Grant DM, McGhee EJ, Owen DM, Zhang W, et al. High speed unsupervised fluorescence lifetime imaging confocal multiwell plate reader for high content analysis. J Biophotonics 2008;1: 514-21.
51. Grant DM, Zhang W, McGhee EJ, Bunney TD, Talbot CB, Kumar S, et al. Multiplexed FRET to image multiple signaling events in live cells. Biophys J 2008;95:L69-71.
52. Kumar S, Alibhai D, Margineanu A, Laine R, Kennedy G, McGinty J, et al. FLIM FRET technology for drug discovery: automated multiwellplate high-content analysis, multiplexed readouts and application in situ. Chemphyschem 2011;12:609-26.
53. Grecco HE, Roda-Navarro P, Girod A, Hou J, Frahm T, Truxius DC, et al. In situ analysis of tyrosine phosphorylation networks by FLIM on cell arrays. Nat Methods 2010;7:467-72.
54. Bakker GJ, Andresen V, Hoffman RM, Friedl P. Fluorescence lifetime microscopy of tumor cell invasion, drug delivery, and cytotoxicity. Methods Enzymol 2012;504:109-25.
55. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.